US University starts a clinical trial of a motion exergaming approach to promote self-managing fatigue and pain after head and neck Cancer treatment
Photo by Lucija Ros
The University of South Florida is commencing recruitment for the clinical trial of the A Motion Exergaming Approach for Symptom Management: HNC.
This overall objective of the study is to test an intervention to overcome the PA barriers for head and neck cancer (HNC) patients during the first 6 months after their treatment. PAfitME stands for a personalized Physical Activity intervention with fitness graded Motion Exergames. PAfitME is delivered via a tested mix of FaceTime calls and home visits, uses commercially available exergaming platforms (Wii Fit and Xbox Kinect).
The researchers propose the following specific aims:
1. When compared to an attention control group, determine the effect of PAfitME on fatigue and musculoskeletal pain at week 6, when controlling for age and sex.
2. When compared to an attention control group, determine the effect of PAfitME on functional status and QOL at week 6, when controlling for age and sex.
3. explore if PA self-efficacy, PA enjoyment, and exergame minutes mediate the effect of PAfitME on fatigue and musculoskeletal pain. This study will evaluate 150 post-treatment (radiation, chemotherapy, or chemoradiation) HNC patients in an RCT with an attention control.
Among head and neck cancer (HNC) patients, 92% report fatigue and 73% have pain. A 10% increase in fatigue or pain is associated with a 10-25% reduction in HNC survival. During the critical transition period from the end of active treatment to 6 months post-treatment, untreated physical symptoms negatively impact functional status (ADL) and quality of life (QOL). Fatigue and musculoskeletal pain are known to improve in response to physical activity (PA). However, 51% of HNC survivors rarely engage in any type of PA because of complicated PA barriers.
The condition is Head and Neck Cancer.
A new clinical trial is recruiting patients in the following locations: United States.
The trial officially began on the August 21, 2020 and is planned to complete on November 30, 2024.
The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT04632654
